Co-Diagnostics (NASDAQ:CODX), Inc. has said it will be introducing its upcoming at-home and point-of-care PCR device at a press conference at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo being held September 26-30, 20321, in Atlanta, Georgia.
The press conference is scheduled to take place at 1,00pm ET on Tuesday, September 28, 2021, in room C105 of the Georgia World Congress Center (GWCC), and is expected to provide details on the development of the new PCR Platform and other company updates.
Co-Diagnostics (NASDAQ:CODX) will also be hosting a booth to promote its existing suite of diagnostics products and technology applications - booth #2454, located in Hall C2 of the GWCC.
READ: Co-Diagnostics announces corporate rebranding after period of transformative growth and expansion
At the present time, the company's new device has not been reviewed by the US Food and Drug Administration (FDA) and is not available for sale.
To learn more about the conference, including registration and exhibitor details, investors can visit: https://meeting.aacc.org. The company's press conference will later be made available on the Events and Webcasts section of the Co-Diagnostics website.
Utah-based Co-Diagnostics is a molecular diagnostics company that develops, manufactures and markets a state-of-the-art diagnostics technology. The company's technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA).
It also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.
On September 23, Co-Diagnostics announced a rebranding, which includes a new logo, website, and other related visual assets and marketing materials will take place over the next several months as additional optimization, validation, and clinical studies for the new device are completed prior to submission for FDA and EUA regulatory review.
Contact the author at jon.hopkins@proactiveinvestors.com